Barinthus Biotherapeutics plc (BRNS)
BRNS Stock Price Chart
Explore Barinthus Biotherapeutics plc interactive price chart. Choose custom timeframes to analyze BRNS price movements and trends.
BRNS Company Profile
Discover essential business fundamentals and corporate details for Barinthus Biotherapeutics plc (BRNS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
30 Apr 2021
Employees
105.00
Website
https://www.barinthusbio.comCEO
William J. Enright MBA
Description
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.
BRNS Financial Timeline
Browse a chronological timeline of Barinthus Biotherapeutics plc corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 5 May 2026
Upcoming earnings on 5 Nov 2025
EPS estimate is -$0.41.
Earnings released on 7 Aug 2025
EPS came in at -$0.52 falling short of the estimated -$0.29 by -79.31%.
Earnings released on 7 May 2025
EPS came in at -$0.49 falling short of the estimated -$0.34 by -44.12%.
Earnings released on 20 Mar 2025
EPS came in at -$0.51 falling short of the estimated -$0.50 by -2.00%, while revenue for the quarter reached -$9.17M .
Earnings released on 6 Nov 2024
EPS came in at -$0.21 surpassing the estimated -$0.45 by +53.33%, while revenue for the quarter reached $14.97M .
Earnings released on 8 Aug 2024
EPS came in at -$0.43 falling short of the estimated -$0.42 by -2.38%.
Earnings released on 13 May 2024
EPS came in at -$0.40 surpassing the estimated -$0.64 by +37.50%.
Earnings released on 20 Mar 2024
EPS came in at -$0.45 surpassing the estimated -$0.55 by +18.18%, while revenue for the quarter reached $5.37M , beating expectations by +4.03K%.
Earnings released on 9 Nov 2023
EPS came in at -$0.37 surpassing the estimated -$0.62 by +40.32%.
Earnings released on 10 Aug 2023
EPS came in at -$0.62 falling short of the estimated -$0.59 by -5.08%, while revenue for the quarter reached $334.00K , missing expectations by -52.57%.
Earnings released on 31 Mar 2023
EPS came in at -$0.48 surpassing the estimated -$0.50 by +4.79%, while revenue for the quarter reached $468.00K , missing expectations by -66.57%.
Earnings released on 31 Dec 2022
EPS came in at -$0.56 falling short of the estimated -$0.43 by -32.27%, while revenue for the quarter reached $6.46M , beating expectations by +94.99%.
Earnings released on 30 Sept 2022
EPS came in at $0.22 surpassing the estimated -$0.38 by +157.22%, while revenue for the quarter reached $6.17M , missing expectations by -20.96%.
Earnings released on 30 Jun 2022
EPS came in at $0.41 surpassing the estimated -$0.32 by +227.18%, while revenue for the quarter reached $17.06M , beating expectations by +360.54%.
Earnings released on 31 Mar 2022
EPS came in at $0.07 , while revenue for the quarter reached $15.02M .
Earnings released on 31 Dec 2021
EPS came in at $0.07 surpassing the estimated -$0.31 by +121.94%, while revenue for the quarter reached $268.00K , missing expectations by -92.77%.
Earnings released on 30 Sept 2021
EPS came in at -$0.13 , while revenue for the quarter reached $19.00K .
Earnings released on 30 Jun 2021
EPS came in at -$0.64 falling short of the estimated -$0.38 by -69.83%, while revenue for the quarter reached $35.00K , missing expectations by -65.00%.
Earnings released on 31 Mar 2021
EPS came in at -$0.45 , while revenue for the quarter reached $215.00K .
Earnings released on 31 Dec 2020
EPS came in at -$92.90 , while revenue for the quarter reached $4.82M .
Earnings released on 30 Sept 2020
EPS came in at $3.32 , while revenue for the quarter reached $3.25M .
BRNS Stock Performance
Access detailed BRNS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.